Is Chemo the Key for EGFR Mutation-Positive NSCLC? The Data Too Good to Overlook

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time -0:00

0.5x
0.75x
1x, selected
1.25x
1.5x
1.75x
2x

Chapters

descriptions off, selected

captions settings, opens captions settings dialog
captions off, selected

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

TextColorTransparency

BackgroundColorTransparency

WindowColorTransparency

Font Size

Text Edge Style

Font Family

End of dialog window.

10 seconds

Playback speed

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

Is Chemo the Key for EGFR Mutation-Positive NSCLC? The Data Too Good to Overlook

By Beacon Medical Interchange FEATURING Jack West

9,996 views

November 2, 2018

Dr. Jack West reviews the remarkable results of the NEJ009 trial that tested the combination ...
read more ↘ of carboplatin/pemetrexed with gefitinib as initial therapy compared to gefitinib followed by chemotherapy in patients with EGFR mutation-positive advanced NSCLC.
↖ read less

Comments 2